St2 antigen binding proteins
US-2024368292-A1 · Nov 7, 2024 · US
Humanized anti-interleukin 3 receptor alpha chain antibodies
US10047161B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10047161-B2 |
| Application number | US-201514678356-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 3, 2015 |
| Priority date | Aug 17, 2010 |
| Publication date | Aug 14, 2018 |
| Grant date | Aug 14, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inducing lysis of leukemic cells in a subject with acute myeloid leukemia (AML), the method comprising administering to a subject suffering from AML an isolated or recombinant antibody that is capable of specifically binding to interleukin (IL)-3Rα chain, wherein the antibody comprises: (i) a light chain variable region (V L ) comprising CDRs 1, 2 and 3 as set forth in SEQ ID NOs: 2, 3 and 4, respectively; (ii) a heavy chain variable region (V H ) comprising CDRs 1, 2 and 3 as set forth in SEQ ID NOs: 5, 6 and 7, respectively; and (iii) a heavy chain constant region comprising amino acid substitutions S239D and I332E according to the EU numbering system of Kabat. 2. The method of claim 1 , wherein the antibody is a humanized antibody comprising: (i) a light chain variable region (V L ) comprising an amino acid sequence according to SEQ ID NO: 8 and a heavy chain variable region (V H ) comprising an amino acid sequence according to SEQ ID NO: 9; and (ii) a heavy chain constant region comprising amino acid substitutions S239D and I332E according to the EU numbering system of Kabat. 3. The method of claim 1 , wherein the heavy chain constant region comprises a sequence set forth between residues 121-450 (inclusive) of SEQ ID NO: 11. 4. The method of claim 1 , wherein the antibody is a humanized antibody comprising a light chain comprising a sequence set forth in SEQ ID NO: 13 and a heavy chain comprising a sequence set forth in SEQ ID NO: 11.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10047161B2 cover?
- The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.
- Who is the assignee on this patent?
- Csl Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2866. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).